Cancer, a complex and multifactorial disease, presents a significant challenge to global
health. Despite significant advances in surgical, radiotherapeutic and immunological …

Non-small-cell lung cancer (NSCLC) is the most common form of primary lung cancer. The
discovery of several oncogenic driver mutations in patients with NSCLC has allowed the …

New concepts and drugs have revolutionized medical treatment for cancers. These drugs,
which are very expensive and usually well tolerated, have dramatically improved cancer …

Background Proton-pump-inhibitors (PPIs) are frequently prescribed for the management of
anticancer drug-related gastrointestinal symptoms. Palbociclib is a weak base with pH …

During the past two decades, small-molecule kinase inhibitors have proven to be valuable in
the treatment of solid and haematological tumours. However, because of their oral …

Activating mutations in the epidermal growth factor receptor (EGFR) gene have been
identified as key oncogenic drivers of non-small cell lung cancer (NSCLC). Osimertinib …

Abstract Introduction Approximately 20–33% of all cancer patients are treated with acid-
reducing agents (ARAs), most commonly proton pump inhibitors (PPIs), to reduce …

Proton pump inhibitors (PPIs) are the most commonly used anti-acid drugs worldwide,
including among cancer patients. However, drug-drug interactions between PPIs and other …

High interindividual variability (IIV) of the clinical response to epidermal growth factor
receptor (EGFR) inhibitors such as osimertinib in non-small-cell lung cancer (NSCLC) might …

Background: Proton pump inhibitors (PPIs) are one of the most widely used drugs worldwide
and are overprescribed in patients with cancer; there is increasing evidence of their effects …